Brenntag Strengthens Biopharma Offering With Regulatory-Ready BYPHAR Raw Materials

Brenntag Strengthens Biopharma Offering With Regulatory-Ready BYPHAR Raw Materials

(IN BRIEF) Brenntag has announced the commercial availability of BYPHAR, its new biopharma raw materials portfolio developed to support manufacturers from early R&D to commercial production. The portfolio is designed to simplify raw material selection and help biopharmaceutical manufacturers meet regulatory, quality, traceability and compliance requirements. It supports applications including monoclonal antibodies, recombinant proteins, cell and gene therapies, vaccines, nucleic acid production, antibody-drug conjugates, biosimilars and diagnostic manufacturing. BYPHAR is structured into three tiers: BYPHAR Explore for research and early-stage non-critical applications, BYPHAR Enhance for GMP-compliant manufacturing materials, and BYPHAR Excel for critical applications requiring high levels of quality, compliance and supply assurance. Brenntag will also provide GMP samples through its Pharma GMP Hub and launch a dedicated customer portal in August.

(PRESS RELEASE) ESSEN, 22-Jul-2026 — /EuropaWire/ — Brenntag has announced the commercial availability of BYPHAR, its new biopharma raw materials portfolio designed to support manufacturers from early research and development through to commercial production.

The company, a global distributor of chemicals and ingredients, first introduced the three-tier BYPHAR portfolio during a global brand reveal in April.

BYPHAR has been developed specifically for the biopharmaceutical sector to simplify raw material selection and help manufacturers address increasingly demanding regulatory and quality requirements across the full development and production lifecycle.

The portfolio brings together Brenntag’s global distribution network, regulatory expertise and technical services in a structured offering that enables customers to select raw materials according to application criticality, manufacturing risk and stage of development.

Brenntag said BYPHAR supports a broad range of biopharmaceutical applications, including monoclonal antibodies, recombinant proteins, cell and gene therapies, vaccines, nucleic acid production, antibody-drug conjugates, biosimilars and diagnostic manufacturing.

The launch comes as biopharmaceutical companies face greater regulatory scrutiny, more complex supply chains and growing pressure to accelerate time-to-market.

Brenntag said manufacturers increasingly need confidence in the quality, traceability and compliance of critical raw materials.

BYPHAR has been designed to address these challenges through a regulatory-ready product range supported by comprehensive documentation, global supply reliability and technical expertise.

Gearoid O’Rourke, Senior Director Biopharma at Brenntag Pharma, said BYPHAR represents an important step in how the company supports biopharma customers.

“By combining high-quality raw materials and flexibility with global supply reliability and deep regulatory expertise, we are helping customers accelerate development and ensure the highest standards of all manufacturing stages,” said O’Rourke.

The BYPHAR portfolio is organised into three product categories aligned with manufacturing risk and development stage.

BYPHAR Explore is designed for research, process development and early-stage manufacturing. It includes non-GMP materials intended for non-critical applications, with products supplied with essential regulatory documentation and monograph compliance where applicable.

BYPHAR Enhance provides GMP-compliant raw materials suitable for use across biopharmaceutical manufacturing. The products are produced in accordance with IPEC and EXCiPACT guidelines and include regulatory-ready documentation to support qualification and validation activities.

BYPHAR Excel is intended for critical manufacturing applications. It offers low-bioburden and low-endotoxin raw materials produced under GMP conditions, with multi-compendial products where applicable and extensive documentation to support quality, compliance and supply assurance.

Brenntag said GMP samples for all BYPHAR products are available and will be released from the company’s Pharma GMP Hub.

To support customer access to product specifications, fact sheets and regulatory documentation packages, Brenntag plans to launch a dedicated customer portal in August.

Alongside Brenntag’s own-label products, BYPHAR also includes co-branded materials from established manufacturing partners, including Budenheim, Citribel, K+S and Kerry.

The combined portfolio gives customers access to high-purity phosphates, citric acid and citrates, pharmaceutical-grade salts and acetates, supported by manufacturing expertise and global supply capabilities.

By integrating global sourcing, quality systems, technical services and regulatory support under one brand, Brenntag said BYPHAR is intended to help biopharma companies move beyond transactional procurement and toward more strategic supply partnerships.